SCHEMBL30765699

SCHEMBL30765699

CCCCOC(=O)Cn1c([S+](C)[O-])ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
LMNA P02545 3/20 0.36
MAPT P10636 5/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35
GABRA6 Q16445 1/20 0.35
GABRG1 Q8N1C3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765510 0.88 L3MBTL1 (0.41) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765675 0.86 L3MBTL1 (0.40) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765767 0.86 GAA (0.40) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30766030 0.86 L3MBTL1 (0.40) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765977 0.86 GAA (0.51) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765742 0.86 GAA (0.39) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765471 0.86 GAA (0.39) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765969 0.84 GAA (0.42) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30766034 0.84 GAA (0.38) GAAL3MBTL1KMT2AMEN1LMNA
SCHEMBL30765801 0.82 LMNA (0.41) GAAL3MBTL1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed